Eptinezumab plus education sustains chronic migraine and medication-overuse headache reductions for 24 weeks
Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial.
Abstract
Eptinezumab 100 mg IV combined with patient education sustained significant reductions in monthly migraine days and active CM/MOH diagnoses over 24 weeks.